VTRS Stock Analysis — Viatris
Sector: Healthcare
AI Verdict
Viatris trades at 6.1x next year's earnings, which is cheap for the sector, but the negative -3.0% revenue growth and lack of a proprietary moat mean you're betting on cost cuts or a turnaround, not a structural edge.
Competitive Moat
Viatris operates as a generic and specialty pharmaceutical manufacturer, leveraging global scale and a vast portfolio to negotiate favorable supply chain terms and distribution access. Its moat is primarily cost efficiency and regulatory expertise, not proprietary drugs or unique data assets.
Summary
Viatris trades at just 6.1x forward earnings, catching attention for its deep value despite shrinking sales.
Where It Stands
With a forward P/E of 6.1x versus the healthcare sector median of 22x and a -3.0% revenue decline, the stock looks cheap but reflects pessimism about growth.
Key Metrics
- Forward P/E: 6.1x
- Revenue Growth: -0.0%
- Dividend Yield: 0.03%
- 52-Week High: $16.47
- 52-Week Low: $7.94
Analyst Consensus
12 Buy · 5 Hold · 1 Sell (18 analysts)
Bull Case
The 6.1x forward P/E is less than one-third of the sector median, suggesting the market is already pricing in a lot of bad news.
Bear Case
If the P/E rises even halfway to the sector median on no growth, the stock could see a sharp correction if earnings disappoint further.
Catalyst to Watch
Watch for regulatory approvals or pipeline updates, as any positive surprise could force a re-rating from the current 6.1x multiple.